These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 14662623)
1. Role of the natriuretic peptide system in cardiorenal protection. McFarlane SI; Winer N; Sowers JR Arch Intern Med; 2003 Dec 8-22; 163(22):2696-704. PubMed ID: 14662623 [TBL] [Abstract][Full Text] [Related]
2. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Savoia C; Volpe M; Alonzo A; Rossi C; Rubattu S Clin Sci (Lond); 2009 Nov; 118(4):231-40. PubMed ID: 19886866 [TBL] [Abstract][Full Text] [Related]
3. Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. Gilbert RE; Douglas SA; Krum H Curr Opin Investig Drugs; 2004 Mar; 5(3):276-82. PubMed ID: 15083593 [TBL] [Abstract][Full Text] [Related]
4. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Abassi Z; Karram T; Ellaham S; Winaver J; Hoffman A Pharmacol Ther; 2004 Jun; 102(3):223-41. PubMed ID: 15246247 [TBL] [Abstract][Full Text] [Related]
5. [Clinical development of drugs related to natriuretic peptides]. Furuya M Nihon Rinsho; 2004 Sep; 62 Suppl 9():170-5. PubMed ID: 15506363 [No Abstract] [Full Text] [Related]
6. Natriuretic peptides in children: physiology and clinical utility. Lenz AM Curr Opin Pediatr; 2011 Aug; 23(4):452-9. PubMed ID: 21602682 [TBL] [Abstract][Full Text] [Related]
7. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Rubattu S; Sciarretta S; Valenti V; Stanzione R; Volpe M Am J Hypertens; 2008 Jul; 21(7):733-41. PubMed ID: 18464748 [TBL] [Abstract][Full Text] [Related]
8. Natriuretic peptides and cardio-renal disease. Volpe M Int J Cardiol; 2014 Oct; 176(3):630-9. PubMed ID: 25213572 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential for existing and novel forms of natriuretic peptides. Chen HH; Burnett JC Heart Fail Clin; 2006 Jul; 2(3):365-73. PubMed ID: 17386905 [No Abstract] [Full Text] [Related]
10. Sympathetic activation in cardiovascular and renal disease. Grassi G; Arenare F; Pieruzzi F; Brambilla G; Mancia G J Nephrol; 2009; 22(2):190-5. PubMed ID: 19384835 [TBL] [Abstract][Full Text] [Related]
11. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Cataliotti A; Chen HH; Redfield MM; Burnett JC Heart Fail Clin; 2006 Jul; 2(3):269-76. PubMed ID: 17386896 [No Abstract] [Full Text] [Related]
12. Natriuretic peptides and renal insufficiency: clinical significance and role of renal clearance. Freda BJ; Francis GS Heart Fail Clin; 2006 Jul; 2(3):277-90. PubMed ID: 17386897 [No Abstract] [Full Text] [Related]
13. C-type natriuretic peptide in vascular physiology and disease. Scotland RS; Ahluwalia A; Hobbs AJ Pharmacol Ther; 2005 Feb; 105(2):85-93. PubMed ID: 15670620 [TBL] [Abstract][Full Text] [Related]
14. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Cataliotti A; Chen HH; James KD; Burnett JC Trends Cardiovasc Med; 2007 Jan; 17(1):10-4. PubMed ID: 17210472 [TBL] [Abstract][Full Text] [Related]